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Abstract: Plaque rupture and thromboembolism play a major role in
atherosclerotic acute syndrome. Experimental studies have demon-
strated the potential direct anti-atherosclerotic effects of calcium an-
tagonists. We investigated the in vitro effect of lercanidipine (REC
15/2375), a third-generation, highly lipophilic calcium antagonist on
cholesterol metabolism and matrix metalloproteinases secretion in
macrophages, two functions that predispose plaques to rupture. Ler-
canidipine (10−6–10−5 M) inhibited cholesterol esterification in mac-
rophages and reduced cellular free and esterified cholesterol accumu-
lation from acetylated LDL (63%, 62% of control P < 0.05,
respectively). In addition, lercanidipine inhibited the release of me-
talloproteinases in the extracellular medium (50% and 95% inhibition
at 10−5 M for MMP-9 and MMP-2, respectively). Experiments per-
formed with lercanidipine enantiomers or other dihydropyridine de-
rivatives, endowed with different lipophilicity and affinity for cal-
cium channels, indicated that the above effects could be related to the
lipophilic, but not to the calcium channel blocking properties of these
molecules. When cells, after exposure to the drug, were allowed to
equilibrate, lercanidipine inhibitory action could be observed at initial
concentrations as low as 10−9 M, which is the actual concentra-
tion range observed in plasma in clinical settings. In conclusion, our
data indicate that lercanidipine may exert potent anti-atherosclerotic
effects by inhibiting macrophage functions involved in plaque
stability.
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Pharmacological control of atherosclerosis may be achievedby both controlling cardiovascular risk factors and by di-
rectly modulating major cellular processes involved in ath-
eroma formation. The composition and vulnerability of plaque
are major determinants of atherosclerosis complications, such
as plaque disruption and superimposed thrombosis.1 Macro-
phages infiltrated in the lesion play a major role in determining
its stability. These cells may accumulate esterified cholesterol
in the atheromatous core and may weaken the fibrous cap by
secreting specific metalloproteinases (MMPs) that degrade the
extracellular matrix.2,3 The well-documented therapeutic effi-
cacy of statins may at least in part be due to their ability to
directly modulate these two macrophages functions.4,5 Dihy-
dropyridine calcium antagonists (CAs) are among the first
drugs showed to possess a direct anti-atherosclerotic activity in
experimental models.6 However, clinical trials either did not or
only weakly supported the relevance of this effect in hu-
mans.7,8 In our laboratory, we previously demonstrated that
the lipophilic CA lacidipine, but not nifedipine, may inhibit
AcylCoA:cholesterol Acyl Transferase (ACAT) in macro-
phages and consequently the intracellular cholesteryl esters
formation,9 and may inhibit also the secretion of metallo-
proteinases.10 Moreover, a direct effect on the arterial wall
was consistently observed in vivo in rabbits.9,11 The anti-
atherosclerotic effect of lacidipine appeared to be unrelated to
calcium channel blockade or blood pressure reduction.9–11 Re-
cently a large clinical trial with lacidipine, the European Laci-
dipine Study on Atherosclerosis (ELSA), has confirmed the
anti-atherosclerotic activity of the drug in humans. The prin-
cipal results showed that long-term antihypertensive treatment
with lacidipine slowed down the progression of carotid intima-
media thickness (IMT) in hypertensive patients to a greater
extent than treatment using the -blocker atenolol. The greater
anti-atherosclerotic action of lacidipine with respect to ateno-
lol seemed to be independent of the blood pressure-lowering
effect, as 24-hour ambulatory systolic and diastolic blood pres-
sure reductions were slightly lower in lacidipine-treated than
in atenolol-treated subjects. No significant difference between
treatments was found in any cardiovascular events, although
Received for publication January 30, 2004; accepted June 30, 2004.
From the *Department of Pharmacological Sciences, University of Milan, Mi-
lan, Italy; †Department of Pharmacological and Biological Sciences and
Applied Chemistries, University of Parma, Italy; ‡Pharmaceutical R&D
Recordati SpA, Milan, Italy.
This study was supported in part by grant No QLG1-1999-01007 from the
European Commission to the consortium “Macrophage Function and Sta-
bility of the Atherosclerotic Plaque (MAFAPS)” as part of the Fifth Frame-
work Program of the European Union and by a grant from Compagnia di San
Paolo and the Italian Ministry of University and Research (MIUR-FIRST).
Reprints: Monica Canavesi, Department of Pharmacological Sciences, Uni-
versity of Milan, via Balzaretti, 9, Milan, Italy 20133 (e-mail: fulab@
unimi.it).
Copyright © 2004 by Lippincott Williams & Wilkins
416 J Cardiovasc Pharmacol • Volume 44, Number 4, October 2004
the relative risk for stroke, major cardiovascular events, and
mortality showed a trend favoring lacidipine.12
Lercanidipine is a new calcium antagonist with high li-
pophilicity and a chiral center. Its pharmacokinetic and phar-
macodynamic characteristics are similar to lacidipine and it is
classified as a once-a-day CA. Lercanidipine and lacidipine
long duration of action are controlled by the tissue cell mem-
brane compartment from which they are slowly released once
they have distributed throughout the patient’s body.13 There-
fore, these two lipophilic CA combine a relatively short
plasma half-life, a gradual onset of action, and an intrinsically
long duration of action. Lercanidipine has been previously
shown to exert anti-atherosclerotic effects in rabbits; it reduced
the hyperplasia and fatty streaks with a significant and dose-
dependent effect in the thoracic and abdominal aorta, but with-
out affecting plasma cholesterol levels. This action was also
observed with its R-enantiomer that has an affinity for calcium
channels two orders of magnitude lower than lercanidipine.14
In the present study we investigated the effects of ler-
canidipine on cellular functions involved in plaque stability,
by evaluating its ability to inhibit cholesterol esterification,
AcLDL-derived cholesterol accumulation, and metallopro-
teinases secretion in mouse peritoneal macrophages in culture
and in human monocytes.
METHODS
Dulbecco minimum essential medium (DMEM), Peni-
cillin-Streptomycin (10000 IU/ml–10000 UG/ml), and fetal
calf serum (FCS) were purchased from GIBCO BRL (Life
Technologies, Milan, Italy). Essentially fatty acid-free bovine
serum albumin (EFAF) was obtained from Sigma Chemical
Company (St. Louis, MO). Cell culture wells (35 mm, Mul-
tidish Nunclon) were obtained from NUNC (Roskilde, Den-
mark).
Cells
Mouse peritoneal macrophages (MPM) were obtained
by peritoneal lavage from mice (BALB/c, Charles River,
Calco, Italy), 3 days after intraperitoneal injection of thiogly-
collate. Cells (2–3 × 106) were plated in 35-mm wells with
DMEM containing 10% FCS. After 2 hours, the dishes were
washed to eliminate unattached cells and maintained in
DMEM plus 10% FCS for 24 hours before use.
Circulating human monocytes were isolated from blood
of healthy donors as previously described.5 The monocytes
were collected, washed, resuspended in serum free DMEM,
and plated at a density of 3 × 106 cells in a 35-mm dish. After
2 hours, cell monolayers were washed twice and the adherent
cells were incubated for 10 to 14 days with DMEM containing
10% human AB serum and insulin 8 µg/ml, to allow for differ-
entiation in macrophages.
Experiments were performed at 37°C in serum free
DMEM containing 0.2% EFAF and the indicated concentra-
tions of drugs, in presence or absence of phorbol esters [phor
bol-12-myristate-13-acetate (PMA), 50 ng/ml] or tumor necrosis
factor- (TNF-, 20 ng/ml) (Sigma Aldrich, St. Louis, MO).
Cellular protein content was measured according to
Lowry et al.15 Cellular viability was assessed using the di-
methylthiazoldiphenyltetrazolium bromide (MTT) assay as
described.16 No cellular toxicity was observed at the drug con-
centrations tested.
Lipoprotein Preparation
Human LDL (d = 1.019–1.063 g/ml) were isolated from
plasma of healthy volunteers by sequential ultracentrifugation
(Beckman L5-50, Palo Alto, CA).17 For acetylation, LDL were
dialyzed against 0.15 M NaCl, pH 7.4, diluted with an equal
volume of saturated Na acetate, and treated with acetic anhy-
dride, according to Basu et al.18
AcLDL were radiolabeled with [3H]-cholesteryl linole-
ate (Amersham, Buckinghamshire, UK) ([3H]-CE-AcLDL) by
incubation with serum containing the cholesteryl ester transfer
protein.19 All lipoproteins were sterile filtered.
Cholesterol Esterification Assay (ACAT Activity)
Cells were incubated with the drug and AcLDL (50
µg/ml) as indicated. Cholesterol esterification was measured
after addition of [1-14C]oleic acid (0.68 µCi/sample) com-
plexed with bovine serum albumin during the last 2 hours of
incubation and subsequent determination of radioactivity as-
sociated with cellular cholesteryl esters.20
At the end of incubation, cells were washed with phos-
phate-buffered saline (PBS) and lipids were extracted with
hexane/isopropanol (3:2). The extracted lipids were separated
by thin layer chromatography (TLC) (isooctane/diethyl
ether/acetic acid, 75:25:2, vol/vol/vd). Cholesterol radioactiv-
ity in the spots was determined by liquid scintillation counting
(Insta-Fluor, Packard, Groningen, The Netherlands).
Intracellular Distribution of
Lipoprotein-Derived Cholesterol
Mouse peritoneal macrophages were incubated with le-
rcanidipine for 30 hours and then with the drug and [3H]-CE-
AcLDL (30 µg protein/ml). The medium was subsequently
discarded, cells were washed with PBS, and the lipids were
extracted with hexane: isopropanol (3:2, vol/vol). Free and es-
terified cholesterol were partitioned by TLC and the radioac-
tivity of the spots was determined by liquid scintillation count-
ing (Insta-Fluor, Packard, Groningen, The Netherlands).
SDS Page Zymography
At the end of the incubation, the conditioned media were
collected and MMPs gelatinolytic capacity was evaluated as
described previously.5 Briefly, samples underwent electropho-
resis on polyacrylamide gels containing SDS and gelatin (1
mg/ml) under non-reducing conditions. After washes, the gels
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were incubated overnight at 37°C with gentle shaking in TRIS
50 mM pH 7.5 containing NaCl 150 mM, CaCl2 10 mM, ZnCl2
1 µM, to activate the metalloproteinase ability to digest the
substrate. At the end of the incubation, the gels were stained
with a solution of Coomassie brilliant blue R-250 (Sigma-
Aldrich, Milan, Italy). Clear zones against the blue back-
ground indicated the presence of proteinolytic activity. It has
been described that, in this type of SDS-containing gel, the
latent form of MMP-9, the pro-MMP-9, and the activated
gelatinase develop gelatinolytic activity21; therefore, we used
the word “activity” to indicate the potential total gelatinolytic
capacity measured in the conditioned media. We have previ-
ously shown5 that, in our experimental conditions, the gelati-
nolytic capacity is due entirely to the 92-kDa proMMP-9, as
assessed by zymography and by Western blot analysis with a
specific antibody against human MMP-9.
ELISA
The amount of secreted MMP-9 protein was quantified
using the highly specific Biotrak™ Matrix Metalloprotein-
ase-9 ELISA system (Amersham Pharmacia, Milan, Italy).
The MMP-9 assay uses 2 antibodies directed against different
epitopes of human MMP-9 and does not show detectable
cross-reactivity with MMP-1, -2, and -3, and TIMP-1 and -2
(Amersham Pharmacia, Milan, Italy). Aliquots of conditioned
media were analyzed as suggested by manufacturer.
Statistical Analysis
For quantitation of zymograms, densitometric scanning
was performed using a system incorporating a video camera
and a computer analysis package (NIH Image 1.52 image
analysis software) as in reference 5. Each experiment was per-
formed at least 3 times with different preparations of cells. Re-
sults were normalized by cellular protein content and ex-
pressed as optical density (O.D.) units.
Data are expressed as mean ± SD (SD). The results were
analyzed by one way analysis of variance (ANOVA) for the
comparison of multiple groups, followed by a Dunnet test.
RESULTS
Lercanidipine was evaluated for its effect on ACAT ac-
tivity in mouse peritoneal macrophages. The results indicated
that the drug was able to inhibit up to 90% in a concentration-
dependent manner the formation of esterified cholesterol in-
duced by AcLDL with an IC50 of 2.37 µmol/l (Fig. 1). We next
evaluated the effect of lercanidipine on macrophage content of
AcLDL-derived cholesterol. To this aim macrophages were
incubated for 30 hours with lercanidipine, followed by an in-
cubation with the drug and [3H]CE-AcLDL for an additional
18 hours. After the incubation period, cells were tested for their
content of radioactive free, esterified, and total cholesterol.
Results in Table 1 indicate that lercanidipine reduced both free
and esterified cellular [3H]cholesterol, resulting in an overall
reduction in total AcLDL-derived cellular cholesterol content.
To investigate whether the inhibitory effect of lercanidipine
was related to its calcium antagonist property, we evaluated
the effect on ACAT activity of lercanidipine enantiomers
and of four 1,4 DHPs: Rec 15/2513, 15/2516, 15/2520,
15/2550, in addition to the well-known dihydropyridine CA
nitrendipine. These compounds differ or not in their ability to
block calcium channels, lipophilicity, or the presence of
ionizable amino group(s). Compounds with lower lipophilicity
(15/2520 and nitrendipine) inhibited cholesterol esterifica-
tion by less than 30%; the molecules with higher lipophilicity,
instead, exerted a more evident effect (40 to 95%) (Table 2).
No correlation was observed with compound affinities for
calcium channels or with the presence of ionizable amino
group.
We next evaluated the effect of lercanidipine on the se-
cretion of MMP-9 by macrophages. MMP-9 is expressed by
virtually all activated macrophages, and has been shown to be
present in atherectomy materials from unstable angina.22
Mouse peritoneal macrophages treatment of 24 hours with
lercanidipine significantly reduced, in a concentration-depen-
dent manner, the gelatinolytic activity of MMP-9 secreted
from 10 to 50%, as assessed by gelatin zymography (Fig. 2).
The two enantiomers reduced macrophage gelatinolytic activ-
ity to the same extent (Fig. 3). To better describe the base of
this action, we measured lercanidipine effect on the gelatino-
lytic potential of MMP-9 already secreted. In this experimental
condition, lercanidipine was ineffective (data not shown), sug-
gesting that the reduced gelatinolytic activity measured by zy-
mography is due to the inhibition of MMP-9 released by cells.
To further confirm this, we measured directly the amount of
FIGURE 1. Effect of lercanidipine on cholesterol esterification
in mouse macrophages. Cells were incubated for 24 hours in
DMEM+EFAF 0.2% and lercanidipine, then with lercanidipine
and AcLDL for 24 hours. In the last 2 hours [14C]-oleic acid
albumin complex was added for the determination of choles-
terol esterification (ACAT activity). *P<0.01 vs control.
Canavesi et al J Cardiovasc Pharmacol • Volume 44, Number 4, October 2004
418 © 2004 Lippincott Williams & Wilkins
MMP-9 released by human macrophages incubated with ler-
canidipine, using an ELISA assay. In this experiment we
showed a reduction of the amount of MMP-9 protein actually
released by cells into the culture medium (control 0.301 ± 0.06,
lercanidipine 5 µM 0.199 ± 0.006 ng MMP-9/µg cellular pro-
tein; P < 0.01).
In our experimental conditions, macrophages also se-
creted MMP-2, the constitutive form of the gelatinases. Ler-
canidipine also inhibited, in a concentration-dependent man
ner, the gelatinolytic activity of MMP-2, from 20 to 95% (Fig. 2).
As reported in Table 3, the drug was still effective in
activated murine macrophages, when metalloproteinases ex-
pression was stimulated by treatment with TNF-, or in human
macrophages stimulated by treatment with phorbol esters.
The concentrations of lercanidipine active in all the
above experiments were higher than its plasma concentrations
observed in humans (in the range of nM). Since lercanidipine
is slowly released from the plasma membrane, we hypoth-
esized that the drug could require some time to equilibrate
within the intracellular pools where it could exert its inhibitory
activity on macrophage functions. To investigate this aspect,
cells were incubated with lercanidipine for 24 hours and then
the drug was removed from cells. The evaluation of cholesterol
esterification was performed 48 hours afterward. The results
indicated that in these conditions lercanidipine not only main-
tained its inhibitory activity, but it was also more potent than
what was observed with shorter experiment duration. In fact, a
60% inhibition of ACAT activity was seen at a concentration
as low as 1 nM (Fig. 4). At the same concentration we also
observed an inhibition of metalloproteinases gelatinolytic ac-
tivity (50% and 65% for MMP-9 and MMP-2, respectively;
Fig. 5).
TABLE 2. Physico-Chemical Properties and Effect on Cholesterol Esterification of Nitrendipine, Lercanidipine, and
Its Derivatives
R
Ca++-Channels
Affinity
Ki BDG (nM)
Lipophilicity
(Log K’w)
Ionizable
Amino
Group(s)
ACAT
Activity in MPM
% of Inhibition
(5 µM)
IC50
(µM)
C(CH3)2CH2NHCH3 Rec 15/2520 ∼1000 3.60 Yes 25.9 ± 4.75 N.C.
CH2CH3 Nitrendipine 0.10 4.50 No 25.4 ± 12.9 N.C.
(*) C(CH3)2CH2N(CH3)CH2CH2CH(C6H5)2 Rec 15/2513 >1000 7.40 Yes 39.6 ± 7.28 9.40
C(CH3)2CH2N(CH3)CH2CH2CH(C6H5)2 (S)-lercanidipine 0.11 7.35 Yes 47.6 ± 0.71 4.52
(**) C(CH3)2CH2N(CH3)CH2CH2CH(C6H5)2 Rec 15/2516 169.8 7.26 Yes 68.8 ± 1.65 3.54
C(CH3)2CH2N(CH3)CH2CH2CH(C6H5)2 (R)-lercanidipine 37.8 7.35 Yes 69.2 ± 1.25 1.88
C(CH3)2CH2N(CH3)COCH2CH(C6H5)2 Rec 15/2550 4.30 6.80 No 97.2 ± 0.32 0.81
(*)Oxidized to pyridine ring; (**) Nitro group at position 4 of the phenyl ring.
Ca++-channels affinity values (evaluated as displacement of [3H]nitrendipine binding from rat brain membranes) and lipophilicity values have been purchased
by Pharmaceutical R&D Division, Recordati S.p.A., Milan, Italy.
TABLE 1. Effect of Lercanidipine on Cholesterol Distribution in Mouse Macrophages Incubated
with [3H]CE-AcLDL
Free Chol
Esterified Chol
(dpm/mg prot. × 103) Total Chol
Control 22.2 ± 3.1 14.6 ± 2.6 45.8 ± 1.8
Lercanidipine 1 µM 16.3 ± 2.9 11.3 ± 2.4 33.7 ± 1.5**
Lercanidipine 10 µM 13.9 ± 2.3* 9.1 ± 1.8* 21.9 ± 3.7**
(3-[decyldimethylsilyl]-N-[2-(4-methylphenyl)-
1-phenylethyl] propanamide) 2.15 µM 22.3 ± 4.5 7.7 ± 1.3* 37.5 ± 5.3*
Cells were incubated with drugs for 30 hours and then with drugs and [3H]CE-AcLDL (30 µg/ml) for 18 hours. At the end
of incubations cellular cholesterol content was determined as described in Methods.
*P < 0.05; **P < 0.01 vs control.
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DISCUSSION
Lercanidipine is a once-a-day calcium antagonist of the
third generation. As reported for lacidipine, its long duration of
action is due to its high lipophilicity. In the present study we
showed that lercanidipine inhibited in a concentration-
dependent manner cholesterol esterification in macrophages in
culture. Similar to what was observed with lacidipine, this ef-
fect was observed also in a cell free homogenate (data not
shown), confirming the ability of these compounds to directly
interfere with the ACAT enzyme. Interestingly, lercanidipine-
treated cells exposed to radioactive cholesteryl esters labeled
AcLDL had a reduced content of both free and esterified ra-
dioactive cholesterol as compared with control. This result in-
dicates that, despite the inhibitory action of lercanidipine on
cholesterol esterification, the drug did not induce accumula-
tion of cholesterol in the free fraction and cells exposed to the
drug had a reduced ability to accumulate lipoprotein-derived
cholesterol. This observation suggests that lercanidipine in-
hibitory effect on cellular cholesteryl ester formation is not
entirely due to a direct ACAT inhibition, but additional mecha-
nisms should be envisioned. This conclusion is supported by
our observation that the addition of lercanidipine (10−6 M) to
macrophages incubated with the specific ACAT inhibitor (3-
FIGURE 3. Effect of lercanidipine enantiomers on MMP-9 ac-
tivity in mouse macrophages. Cells were incubated for 24
hours in DMEM+EFAF 0.2% and lercanidipine enantiomers.
The gelatinolytic activity of MMP-9 in the media was analyzed
by gelatin zymography. *P < 0.05; **P < 0.01 versus control.
FIGURE 4. Effect of lercanidipine on cholesterol esterification
in mouse macrophages after a period of washout. Cells were
incubated for 24 hours in DMEM+EFAF 0.2% and lercani-
dipine; then with a drug-free medium for 48 hours. At the end
all cells underwent 2 hours’ incubation in presence of AcLDL
and [14C]-oleic acid albumin complex. *P < 0.01 versus con-
trol; ° P < 0.01 versus lercanidipine alone.
FIGURE 2. Effect of lercanidipine on MMPs gelatinolytic activ-
ity in mouse peritoneal macrophages. Cells were incubated for
24 hours in DMEM+EFAF 0.2% and lercanidipine. The gelati-
nolytic activity of MMP-9 and MMP-2 in the media was ana-
lyzed by gelatin zymography as described in Methods. *P <
0.01 versus control.
TABLE 3. Effect of Lercanidipine on MMP-9 Gelatinolytic
Activity in Activated Macrophages
MMP-9 Gelatinolytic Activity
(O.D./µg cell. protein)
Mouse Macrophages
Control 8.7 ± 0.3
TNF- 20 ng/ml 12.6 ± 0.9
TNF-+ Lercanidipine 1 µM 9.0 ± 0.4*
Human Macrophages
Control 4.7 ± 0.8
PMA 50 ng/ml 7.3 ± 0.4
PMA + Lercanidipine 1 µM 5.2 ± 0.4*
Cells were incubated with lercanidipine and TNF- or PMA for 24 hours.
At the end of incubations gelatinolytic capacity was determined as described in
Methods.
*P < 0.01 vs TNF- or PMA alone.
-
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[decyldimethylsilyl]-N-[2-(4-methylphenyl)-1-phenylethyl]
propanamide), leads to a further reduction of the cellular con-
tent of esterified cholesterol (from 5.5 to 3.7 dpm/mg prot. ×
103) without any increase in the free form. This effect could be
explained by a possible increase in cholesterol efflux, a hy-
pothesis supported by Robenek and Schmitz23 and, more re-
cently, by Suzuki et al,24 who showed that calcium antagonists
may increase cellular cholesterol release by different mecha-
nisms.
We previously demonstrated that lacidipine, but not ni-
fedipine, was able to inhibit cholesterol esterification in cell
culture.9 This led to the hypothesis that the lipophilic proper-
ties of the former were involved in the drug inhibitory activity,
independently of the affinity for calcium channels. In this
study, we compared the effect on cholesterol esterification of
the highly lipophilic lercanidipine with those of its two enan-
tiomers and with a series of dydrophyridine derivatives with
different degree of lipophilicity, affinity for the calcium chan-
nels, and containing or not a charged amino group. According
to the previous hypothesis, both lercanidipine’s enantiomers
were active despite their different calcium channel blockade
properties and the results suggested the involvement of lipo-
philicity as a necessary property for the inhibitory activity of
cellular esterification, but not of calcium channel blockade.
Since the activity of ACAT is sensitive to variations in the
lipophilicity and composition of the biophase,25 the presence
of the drug could alter the availability of the substrate for the
enzyme. However, other structural characteristics of the mol-
ecules seem to be involved, as suggested by the differences in
efficacy and potency among compounds in the high range of
lipophilicity. In particular a stereospecific mechanism for
ACAT inhibition and the influence of ionizable amino
group(s) could be envisioned.
Lercanidipine and both its enantiomers were also
equally effective in reducing the gelatinolytic activity, mea-
sured in the media of treated macrophages, again suggesting an
effect independent of calcium channels blockade. The effect of
lercanidipine on gelatinolytic activity in the extracellular me-
dia is consequent to the decreased secretion of MMP-9 by
cells. This observation is supported by the evidence that ler-
canidipine was not able to interfere directly with the gelatino-
lytic potential of media once the proteolytic enzymes have
been already secreted and by the reduction of the actual
amount of MMP-9 present in the incubation media, as mea-
sured by ELISA. This conclusion is entirely consistent with
our previous observation obtained using lacidipine.10
Previous studies demonstrated that lacidipine and ler-
canidipine may exert direct effects on the arterial wall in rab-
bits at doses that give drug plasma concentrations similar to
those observed in humans.9,11,14 Recently, Zanchetti et al12
demonstrated that lacidipine in men reduced IMT progression
and plaque number to a greater extent than atenolol, despite a
similar efficacy in blood pressure-lowering. The latter obser-
vations indicate that the direct effect of lipophilic CA on the
arterial wall, demonstrated in the above-mentioned experi-
mental models, may be relevant also to the clinical practice.
However, the potential anti-atherosclerotic effects previously
reported in cell cultures with lacidipine and, in similar experi-
mental conditions (ie, 24 hours’ incubation) with lercanidipine
in the present study, occurred only at concentrations of the
drugs that were 2 to 3 orders of magnitude higher then those
measured in plasma, raising the question if the in vitro obser-
vations could be relevant to the in vivo effects obtained both in
rabbits and in humans. Previously published data showed that
lercanidipine reduction of the contractility of aorta strips per-
sisted for several hours after removal of the compound from
the bath.26 In addition we observed that lacidipine inhibitory
effect on MMPs secretion by macrophages was maintained up
to 48 hours after removal of the drug from the incubation me-
dia.10 In the present study we show that lercanidipine retains its
ability to inhibit cholesterol esterification and MMP secretion
in macrophages even at 2 days after wash out. In this experi-
mental condition, the initial active concentrations of the drug
were as low as 10−9 M, a concentration 2 to 3 orders of mag-
nitude lower than in shorter experiments and similar to that
observed in human plasma.27 This result suggests that once the
drug has reached the plasma membrane, it slowly equilibrates
within the intracellular pools where it may exert its inhibitory
action on ACAT activity or MMP secretion. Therefore, ler-
canidipine may exert cellular effects in vitro at concentrations
similar to those observed in clinical practice, as long as the
drug has the time to reach the intracellular sites of action, a
condition that occurs during therapy with this drug.
FIGURE 5. Effect of lercanidipine 1 nM on MMPs gelatinolytic
activity in mouse peritoneal macrophages after a period of
washout. Cells were incubated for 24 hours in DMEM+EFAF
0.2% and lercanidipine 1 nM; then with a drug-free medium
for 48 hours. The gelatinolytic activity of MMPs in the media
was analyzed by gelatin zymography as described in Methods.
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CONCLUSION
In conclusion, our present study demonstrates that ler-
canidipine, at concentrations similar to those occurring in
clinical practice, may inhibit in vitro macrophage functions in-
volved in atherogenesis and plaque stability. These observa-
tions may in part explain the direct anti-atherosclerotic action
of lipophilic calcium antagonists reported in animal models
and in humans.
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